- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01113684
Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)
May 9, 2018 updated by: Harrison Walker, MD, University of Alabama at Birmingham
Clinical and Neurophysiological Study of Subthalamic Brain Stimulation in PD
Deep brain stimulation (DBS) improves debilitating symptoms of movement disorders when conventional medical therapies and novel surgical therapies fail.
Despite the remarkable efficacy of DBS, its therapeutic mechanism remains unclear.
There is controversy regarding whether the therapeutic effects of DBS are associated with inhibition or excitation of target neurons, the introduction of new activity into the network, or a combination of these mechanisms.
Additionally, it is unclear why stimulus frequency plays an important role in the clinical response to therapy.
The fundamental hypothesis of this proposal is that unilateral subthalamic nucleus (STN) DBS in PD alters neuronal activity in the bilateral basal ganglia-thalamic-cortical motor system in a manner that is dependent on stimulation frequency.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
175
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with Parkinson's disease who have undergone subthalamic deep brain stimulation
Description
Inclusion Criteria:
- Patients with Parkinson disease who have undergone subthalamic deep brain stimulation
Exclusion Criteria:
- Patients who are unable to follow verbal instructions
- Patients who are unable to tolerate being off their Parkinson's medications for 12 hours
- Patients who are medically unstable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
This study measures neurophysiological responses to subthalamic deep brain stimulation in the central and peripheral nervous system in patients with Parkinson disease.
Time Frame: Population data will be analyzed for the primary endpoint in 12 months and reported in approximately 18 months.
|
Population data will be analyzed for the primary endpoint in 12 months and reported in approximately 18 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Harrison C Walker, MD, University of Alabama at Birmingham, Department of Neurology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (ACTUAL)
November 1, 2014
Study Completion (ACTUAL)
November 1, 2014
Study Registration Dates
First Submitted
April 26, 2010
First Submitted That Met QC Criteria
April 29, 2010
First Posted (ESTIMATE)
April 30, 2010
Study Record Updates
Last Update Posted (ACTUAL)
May 11, 2018
Last Update Submitted That Met QC Criteria
May 9, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F091215017
- 1K23NS067053-01 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Implantable pulse generator (deep brain stimulator)
-
Nora VanegasCompletedParkinson DiseaseUnited States
-
Nora VanegasEnrolling by invitation
-
Nader PouratianMedtronicWithdrawn
-
Medtronic Cardiac Rhythm and Heart FailureCompletedBradycardia | PacemakerGermany, Czech Republic, Austria, Sweden, Netherlands, Former Serbia and Montenegro
-
MetaCure LimitedCompleted
-
Abbott Medical DevicesCompleted
-
Poitiers University HospitalRecruitingChronic Neuropathic PainFrance
-
University College, LondonNot yet recruitingChronic Migraine, Headache | Refractory Migraine
-
Vanderbilt University Medical CenterAbbott Medical DevicesTerminatedBilateral Vocal Fold Paralysis (BVFP)
-
The University of Western AustraliaSir Charles Gairdner Hospital; Perron Institute for Neurological and Translational...WithdrawnTourette's SyndromeAustralia